80 related articles for article (PubMed ID: 19563448)
1. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.
Meijer JA; le Cessie S; van den Hout WB; Kievit J; Schoones JW; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2010 Apr; 72(4):534-42. PubMed ID: 19563448
[TBL] [Abstract][Full Text] [Related]
2. Unexplained increase of serum carcinoembryonic antigen: don't forget the thyroid!
Montes de Jesus FM; Giovanella L
Clin Chem Lab Med; 2023 Sep; 61(10):e203-e205. PubMed ID: 37053395
[No Abstract] [Full Text] [Related]
3. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
Papapetrou PD; Polymeris A
Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
[TBL] [Abstract][Full Text] [Related]
4. Management of Medullary Thyroid Cancer.
Viola D; Elisei R
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):285-301. PubMed ID: 30717909
[TBL] [Abstract][Full Text] [Related]
5. Medullary thyroid carcinoma: a 30-year experience at one institution in Korea.
Lee CR; Lee S; Son H; Ban E; Kang SW; Lee J; Jeong JJ; Nam KH; Chung WY; Park CS
Ann Surg Treat Res; 2016 Dec; 91(6):278-287. PubMed ID: 27904849
[TBL] [Abstract][Full Text] [Related]
6. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Wells SA; Asa SL; Dralle H; Elisei R; Evans DB; Gagel RF; Lee N; Machens A; Moley JF; Pacini F; Raue F; Frank-Raue K; Robinson B; Rosenthal MS; Santoro M; Schlumberger M; Shah M; Waguespack SG;
Thyroid; 2015 Jun; 25(6):567-610. PubMed ID: 25810047
[TBL] [Abstract][Full Text] [Related]
7. Medullary thyroid carcinoma with double negative calcitonin and CEA: a case report and update of literature review.
Gambardella C; Offi C; Clarizia G; Romano RM; Cozzolino I; Montella M; Di Crescenzo RM; Mascolo M; Cangiano A; Di Martino S; Candela G; Docimo G
BMC Endocr Disord; 2019 Oct; 19(1):103. PubMed ID: 31619220
[TBL] [Abstract][Full Text] [Related]
8. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis.
Treglia G; Cocciolillo F; Di Nardo F; Poscia A; de Waure C; Giordano A; Rufini V
Acad Radiol; 2012 Oct; 19(10):1290-9. PubMed ID: 22819076
[TBL] [Abstract][Full Text] [Related]
9. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.
Ceolin L; Duval MADS; Benini AF; Ferreira CV; Maia AL
Endocr Relat Cancer; 2019 Aug; 26(9):R499-R518. PubMed ID: 31252403
[TBL] [Abstract][Full Text] [Related]
10. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Filetti S; Durante C; Hartl D; Leboulleux S; Locati LD; Newbold K; Papotti MG; Berruti A;
Ann Oncol; 2019 Dec; 30(12):1856-1883. PubMed ID: 31549998
[No Abstract] [Full Text] [Related]
11. Time Kinetics and prognosis roles of calcitonin after surgery for medullary thyroid carcinoma.
Guo F; Fu G; Li F; Hua Y; Wang Z; Zheng X; Zhao J; Gao M
World J Surg Oncol; 2024 May; 22(1):121. PubMed ID: 38711029
[TBL] [Abstract][Full Text] [Related]
12. Changes of biochemical factors and the effect on recurrence of medullary thyroid carcinoma after surgery.
Guo F; Li L; Gu P; Zhang G; Ruan X; Zhao J; Zheng X; Wei S; Gao M
Heliyon; 2024 Apr; 10(8):e29857. PubMed ID: 38681571
[TBL] [Abstract][Full Text] [Related]
13. Serum Biochemical Markers for Medullary Thyroid Carcinoma: An Update.
Liu S; Zhao H; Li X
Cancer Manag Res; 2024; 16():299-310. PubMed ID: 38617188
[TBL] [Abstract][Full Text] [Related]
14. Medullary Thyroid Carcinoma: A Single Institute Experience.
Trivedi S; Salahuddin T; Mithi MT; Rathod P; Bandi A; Pandya SJ; Sharma M; Patel S; Warikoo V; Puj K; Salunkhe A; Patel K; Pandya S
Indian J Otolaryngol Head Neck Surg; 2023 Dec; 75(4):2884-2889. PubMed ID: 37974849
[TBL] [Abstract][Full Text] [Related]
15. [Value of Baseline Calcitonin for Differential Diagnosis of Medullary Thyroid Cancer].
Liu QH; Nie X; He Y; Yin MT; Li GX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 54(2):432-438. PubMed ID: 36949711
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic tests for medullary thyroid carcinoma: an umbrella review.
Trimboli P; Mian C; Piccardo A; Treglia G
Endocrine; 2023 Aug; 81(2):183-193. PubMed ID: 36877452
[TBL] [Abstract][Full Text] [Related]
17. Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: A retrospective study.
Jiao Z; Wu T; Jiang M; Jiang S; Jiang K; Peng J; Luo G; Yu Y; Chen W; Yang A
Front Endocrinol (Lausanne); 2022; 13():1094242. PubMed ID: 36589824
[TBL] [Abstract][Full Text] [Related]
18. Does pretreatment elevated calcitonin level cause the poor prognosis in patients with medullary thyroid cancer?
Zhang H; Zhang D; Sui C; Li J; Li C; He Q; Du R; Zhao Y; Fu Y; Zhou L; Wang T; Dionigi G; Liang N; Sun H
Ann Transl Med; 2022 Jun; 10(12):709. PubMed ID: 35845523
[TBL] [Abstract][Full Text] [Related]
19. Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Matrone A; Gambale C; Prete A; Elisei R
Front Endocrinol (Lausanne); 2022; 13():864253. PubMed ID: 35422765
[TBL] [Abstract][Full Text] [Related]
20. The role of thyroglobulin doubling time in differentiated thyroid cancer: a meta-analysis.
Giovanella L; Garo ML; Albano D; Görges R; Ceriani L
Endocr Connect; 2022 Apr; 11(4):. PubMed ID: 35245206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
